Linden Thomas Advisory Services’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.04M Buy
15,463
+422
+3% +$108K 0.32% 78
2026
Q2
$3.78M Buy
15,041
+710
+5% +$153K 0.31% 80
2026
Q1
$3.12M Buy
14,331
+824
+6% +$183K 0.3% 95
2025
Q4
$3.09M Buy
13,507
+407
+3% +$92.7K 0.31% 86
2025
Q3
$3.03M Buy
13,100
+152
+1% +$31K 0.31% 83
2025
Q2
$2.4M Buy
12,948
+561
+5% +$104K 0.26% 112
2025
Q1
$2.6M Buy
12,387
+49
+0.4% +$9.5K 0.34% 81
2024
Q4
$2.19M Buy
12,338
+35
+0.3% +$6.44K 0.28% 113
2024
Q3
$2.43M Sell
12,303
-37
-0.3% -$6.9K 0.33% 79
2024
Q2
$2.12M Sell
12,340
-217
-2% -$35.9K 0.33% 82
2024
Q1
$2.29M Buy
12,557
+94
+0.8% +$16.2K 0.37% 62
2023
Q4
$1.93M Buy
12,463
+121
+1% +$17.6K 0.36% 72
2023
Q3
$1.84M Sell
12,342
-14
-0.1% -$2.06K 0.41% 56
2023
Q2
$1.66M Buy
12,356
+345
+3% +$50.6K 0.37% 73
2023
Q1
$1.91M Buy
12,011
+1,194
+11% +$183K 0.47% 47
2022
Q4
$1.75M Buy
+10,817
New +$1.66M 0.49% 53

Other funds holding ABBV

Linden Thomas Advisory Services's ABBV Position: Q3 2026 in Review

Linden Thomas Advisory Services increased its AbbVie (ABBV) stake by 2.8% in Q3 2026, buying an estimated $108K and bringing the position to 15,463 shares worth $4.04M. The position accounts for 0.32% of the portfolio, ranked #78.

Linden Thomas Advisory Services first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. 1,551 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Linden Thomas Advisory Services held 15,463 shares of AbbVie worth $4.04M as of Q3 2026.
  • Linden Thomas Advisory Services bought 422 AbbVie shares in Q3 2026, an estimated $108K.
  • AbbVie made up 0.32% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #78 holding.
  • Linden Thomas Advisory Services first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
  • 1,551 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.